A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT02716116. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is about a medicine called TAK-788, also known as mobocertinib, given to adults with non-small cell lung cancer. The main aims of this study are to check if there are any side effects from TAK-788, to learn how TAK-788 is processed by the body, and to determine the best dose of TAK-788 to treat this condition. Participants will take TAK-788 capsules with chemotherapy. Participants will continue to take TAK-788 unless they or their doctor decide they should stop this treatment. Participants will take TAK-788 capsules with or without chemotherapy under antidiarrhea prevention to determine the safety of TAK-788 treatment. Non-Asian, non-White participants will take TAK-788 to determine the safety and tolerability of TAK-788 treatment.
Study identification
- NCT ID
- NCT02716116
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 334 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 15, 2016
- Primary completion
- Oct 30, 2026
- Completion
- Oct 30, 2026
- Last update posted
- Feb 24, 2026
2016 – 2026
United States locations
- U.S. sites
- 36
- U.S. states
- 20
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Brookwood Medical Center | Birmingham | Alabama | 35209 | — |
| Banner MD Anderson Cancer Center | Gilbert | Arizona | 85234 | — |
| The Oncology Institute of Hope and Innovation - West Tucson | Tucson | Arizona | 85745 | — |
| City of Hope Comprehensive Cancer Center - Duarte | Duarte | California | 91010 | — |
| Compassionate Cancer Care - Fountain Valley | Fountain Valley | California | 92708 | — |
| University of California San Diego Moores Cancer Center | La Jolla | California | 92093 | — |
| Pacific Shores Medical Group-Long Beach Elm | Long Beach | California | 90813 | — |
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | — |
| University of California Irvine Health Chao Family Comprehensive Cancer Center | Orange | California | 92868 | — |
| Stanford Cancer Center - Palo Alto | Palo Alto | California | 94305 | — |
| SLO Oncology and Hematology Health Center | San Luis Obispo | California | 93405 | — |
| The Oncology Institute of Hope and Innovation | Whittier | California | 90603 | — |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | — |
| AdventHealth Orlando | Orlando | Florida | 32804 | — |
| Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| The University of Chicago Medicine | Chicago | Illinois | 60637 | — |
| Investigative Clinical Research - Indiana | Indianapolis | Indiana | 46260 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | — |
| Siteman Cancer Center - Washington University Medical Campus | St Louis | Missouri | 63110 | — |
| Atlantic Health - Morristown Medical Center | Morristown | New Jersey | 07960 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Levine Cancer Institute | Charlotte | North Carolina | 28203 | — |
| Carolinas Healthcare System | Charlotte | North Carolina | 28204 | — |
| Hightower Clinical | Oklahoma City | Oklahoma | 73102 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Thompson Oncology Group - Knoxville - Downtown | Knoxville | Tennessee | 37916 | — |
| SCRI - Tennessee Oncology - Nashville - Centennial | Nashville | Tennessee | 37203 | — |
| University of Virginia Cancer Center | Nashville | Tennessee | 37232 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| Lumi Research | Houston | Texas | 77090 | — |
| University of Virginia Cancer Center | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists - Fairfax Office | Fairfax | Virginia | 22031 | — |
| Swedish Cancer Institute | Seattle | Washington | 98104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 26 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02716116, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 24, 2026 · Synced Sep 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02716116 live on ClinicalTrials.gov.